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numerous studies and cohorts, complete contemporary percentile-based reference values are underreported.
OBJECTIVE: We set out to provide such reference lipid data using a large contemporary population-
based cohort study.
STUDY DESIGN AND SETTING: Lifelines is a cross-sectional population-based Dutch cohort study. We
analyzed 133,540 adult fasting participants without cardiovascular disease and without lipid-lowering drug
use. Lipid levels were directly measured and selected percentiles of all lipid parameters were calculated.
Friedewald LDL-C estimation was calculated as well.
RESULTS: From 20 till 49 years of age, men were found to exhibit a steep 64% increase of LDL-C
(median 154 mg/dL), while triglyceride levels increased almost two-fold. In women, LDL-C levels did
not change from 18 till 35 years, followed by a steep 42% increase till 59 years (median 142 mg/dL).
In contrast to men, triglycerides were stable in ageing women. Overall, Friedewald LDL-C levels are lower
compared with the direct measurement, especially with increasing triglyceride levels.
CONCLUSIONS: This observational study highlights striking gender- and age-related differences in
plasma lipid profiles. The given reference ranges of plasma lipids can assist in early identification of indi-
viduals with hypocholesterolemia and hypercholesterolemia, especially familial hypercholesterolemia.
These reference ranges are available for physicians and patients at www.my-cholesterol.care/.
 2017 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).y the Netherlands CardioVascular
Genius) and the European Union
91-2). J.A.K. is an Established
undation (2015T068).
to this to this work.
* Corresponding author. Department of Pediatrics, University of Gro-
ningen, Antonius Deusinglaan 1, 9713 AV Groningen, the Netherlands.
E-mail address: j.a.kuivenhoven@umcg.nl
Submitted January 28, 2017. Accepted for publication May 24, 2017.
ociation. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
d/4.0/).
.007
1056 Journal of Clinical Lipidology, Vol 11, No 4, August 2017Introduction
Healthcare in the 21st century is challenged by an
increasing number of people experiencing noncommuni-
cable chronic diseases. Cardiovascular disease (CVD)
affects most men beyond the age of 55 years and women
beyond 65 years of age.1 Consequently, CVD is generally
regarded an ageing disorder. However, it has long been
known that fatty streaks and subsequent plaque formation
already starts at a very young age, and the pace of progres-
sion is related to plasma low-density lipoprotein cholesterol
(LDL-C) levels concentration.2 To curtail this threat, early
prevention seems the preferred approach to curb this expo-
nential increase in avoidable chronic diseases.3,4 From this
perspective, the early identification of modifiable risk fac-
tors, especially dyslipidemia, is key to effective prevention
and management of CVD.2,5
Cohort studies can provide insight in what is needed to
promote ‘‘healthy ageing’’ and find solutions for early
identification and intervention of individuals at increased
CVD risk. The Lifelines cohort study, initiated in 2006, is
the largest ongoing prospective observational European
population study to date.6 Study participants, 152,180 adult
inhabitants of the northern part of the Netherlands, were re-
cruited by their primary care physicians, through family
members or by registering at the Lifelines Website (www.
lifelines.nl). The total duration of follow-up will be
30 years, the first 5-year follow-up visit is in process, the
next 10-year follow-up visit is being planned. Data consist
of self-reported/validated questionnaires, routine clinical
biochemistry, physical examination, biobanking of bioma-
terials including blood, urine, and feces and genome-wide
genotyping. Thereby, the Lifelines study can provide
insight into the prevalence and incidence of multifactorial
diseases and their risk factors, including lipids. Based on
the concepts of modifiers and the three-generation design,
this study may provide better understanding of the causes
and prognosis of dyslipidemia over a lifetime. This may ul-
timately result in optimal tailored treatment of, for
example, hypercholesterolemia, overriding standard pre-
ventive strategies.
Identifying dyslipidemia requires knowledge of the
normal distribution of blood lipids in the population.
Reference values for total cholesterol, LDL-C, high-density
lipoprotein cholesterol (HDL-C), and triglycerides have
been collected in numerous studies and cohorts. However,
contemporary and comprehensive percentile-based refer-
ence values are surprisingly missing. Apart from the broad
variation of these values in different geographical regions,7
there are also time-dependent changes reflecting modifica-
tions in age, lifestyle, and pharmaceutical interventions.8,9
This article aims to provide baseline information and
facilitate future research, by providing age- and gender-
based reference values for lipid levels. These lipid
reference values are indispensable for comparison with
populations from different regions or different geneticbackground, as well as monitoring prospective changes.
Importantly, they can also serve the early identification of
individuals with, for example, familial hypercholesterole-




Lifelines is a large population-based prospective cohort
study conducted in the north of the Netherlands. Partici-
pants of almost exclusively Caucasian descent were
included between 2006 and 2013. The study protocol was
approved by the medical ethics committee of the University
Medical Center Groningen, and all participants provided
written informed consent. The design and rationale of the
study are described elsewhere.6 In short, general practi-
tioners asked their patients, between the age of 25 and
50 years, if they were willing to participate. After a positive
response, family members from all ages (partner, parents,
parents-in-law, and children) were also invited to partici-
pate. In addition, individuals aged $18 years could become
a participant through self-registration. These individuals
were also asked to invite family members.
At baseline, all participants filled out questionnaires and
underwent a comprehensive physical examination. The
questionnaires covered health topics, psychosocial parame-
ters, information on lifestyle, and medication use (including
lipid-lowering drugs). Physical examination included anthro-
pometry, blood pressure measurement, pulmonary function
tests, echocardiogram, and a neuropsychiatric interview.
Fasting blood was drawn from all participants for clinical
chemistry measurements including plasma lipids.
Exclusion criteria
The data of children (aged ,18 years) have not yet been
released and could therefore not be included. Participants
with a history of CVD at baseline, defined as myocardial
infarction, coronary surgery (balloon angioplasty or bypass
surgery) or stroke, were excluded. Transient ischemic attack
and peripheral vascular disease could not be accounted for
because these clinical features could not be adequately
scored with the questionnaires used. In addition, participants
reporting lipid-lowering drug use (ie, statins, fibrates, or
ezetimibe) at baseline, and those with nonfasting blood tests
at baseline were excluded from this analysis.
Cholesterol measurements
Venous blood samples were collected following a
standard protocol, after an overnight fast. Plasma from
heparinized tubes was used for clinical chemistry.
Lipid measurements were performed using Roche Modular
P automated analyzer (Mannheim, Germany). Total
Balder et al Age, gender and lipid levels 1057cholesterol and LDL-C were measured with a direct
enzymatic colorimetric assay using cholesterol esterase
and cholesterol oxidase. Total cholesterol was standardized
against isotope dilution-mass spectrometry and LDL-C was
standardized against the beta quantification method. HDL-
C was measured with a third-generation direct quantitative
enzymatic colorimetric assay using polyethylene glycol-
cholesterol esterase and polyethylene glycol-cholesterol
oxidase and standardized against the CDC reference
method.10 Triglycerides were measured using an assay
based on glycerol phosphate oxidase-peroxidase aminophe-
nazone and standardized against isotope dilution-mass
spectrometry. LDL-C was also calculated with the Friede-
wald formula (total cholesterol 2 HDL-C – [triglyceride/
5.0]). When using this formula, 1387 individuals with tri-
glyceride levels .400 mg/dL were excluded.11 Apolipo-
protein (Apo) B and ApoA-I were only measured in the
first 6038 individuals that were enrolled. Because of the
design of the Lifelines study, these 6038 individuals are be-
tween 25 and 50 years of age. Therefore, the data of Apo B
and Apo A-I are not presented in this study.
Statistical analysis
All analyses were carried out using IBM SPSS Statistics,
version 22.0 (IBM Corp, Armonk, NY). Baseline charac-
teristics of normally distributed variables were reported as
mean and standard deviation. Student’s t-test was used to
compare the means of two groups. Not normally distributed
parameters were reported as median and interquartile
range. Mann–Whitney U test was used to compare the me-
dians between males and females.
Plasma lipid levels were analyzed for men and women
separately at baseline. The 5th, 10th, 25th, 50th, 75th, 90th,
and 95th percentiles were calculated to display the popula-
tion distribution. In addition, the 1st, 2.5th, 97.5th, and 99th
percentiles were calculated. Kruskal–Wallis H test was
used to determine differences in lipid levels between age
groups within gender. Pairwise comparisons were per-
formed using Dunn’s (1964) procedure with a Bonferroni
correction for multiple comparisons. Adjusted P values
are presented. To examine and describe trends of lipids
with age, an adjusted P value (P , .05) was considered
to be significant. To display the difference between calcu-
lated LDL-C and direct measurement of LDL-C, the me-




Of the 152,180 participants, 18,640 (12%) were
excluded because of CVD, use of lipid-lowering drugs
(statins, fibrates, or ezetimibe), nonfasting blood tests, or
missing lipid data (Fig 1). Table 1 shows the baselinecharacteristics of the remaining 133,540 individuals, strati-
fied by gender. The mean age of both men and women was
44 years (range 18–93 years). Our cohort consisted of more
women (79,475; 60%) than men (54,065; 40%). Women
presented with an overall more favorable cardiovascular
risk profile than men: lower mean systolic blood pressure
(122 vs 130 mm Hg; P , .001), lower median total choles-
terol (193 vs 197 mg/dL; P , .001), lower median LDL-C
(116 vs 131 mg/dL; P , .001), higher median HDL-C
(62 vs 50 mg/dL; P , .001), lower triglycerides (77 vs
100 mg/dL; P , .001), and lower smoking rates (19.7 vs
23.3%; P , .001). An approximate quarter of the complete
study population (23.6%) reported to be physically active
for at least 30 minutes every day. Supplementary Table 1
shows the number of individuals included per gender and
age group.
Figures 2 and 3 show the relation between age and blood
lipid levels for men and women, using the 5th, 10th, 25th,
50th, 75th, 90th and 95th percentile lines. The text in the
following sections only describes the main general observa-
tions. To illustrate the significance of some of these obser-
vations, we provide more detailed information for the 95th
percentile or 5th percentile.
Age, gender, and LDL-C levels
At 20 years of age, men presented with significantly
lower LDL-C levels compared with women (median: 85
vs 97 mg/dL; 95th percentile: 139 vs 151 mg/dL;
P , .001). It is clear that in both genders LDL-C
increases with age, but the dynamics were strongly gender
specific: in men, LDL-C increased markedly from
adolescence and peaked at 45 to 49 years of age (median:
139 mg/dL; 95th percentile: 197 mg/dL). At higher ages
LDL-C levels show a gradual decrease. This is illustrated
by men $ 80 years, whose LDL-C levels were
significantly lower than those aged 60 to 64 years
(median: 131 vs 143 mg/dL; 95th percentile: 183 vs
197 mg/dL; P , .001).
In women, by contrast, median LDL-C was stable until
their mid-30s, after, which LDL-C increased to a maximum
at 55 to 59 years (median: 143 mg/dL; 95th percentile:
205 mg/dL). There was no clear decline at higher ages in
women as was observed in men. Another interesting finding
is the enormous distribution of LDL-C levels in this appar-
ently healthy general population. For example, in males,
aged 35 to 39 years, 90% of the LDL-C levels are within
81 and 186 mg/dL.
While the current data were generated with direct lipid
quantification methods, LDL-C is typically calculated
using the Friedewald formula.11 Calculated LDL-C in
our study provides lower values compared with direct
LDL-C quantification for both genders (Supplementary
Fig. 1). The median Friedewald LDL-C was 7.0 mg/dL
lower in men and 6.0 mg/dL lower in women. With
increasing triglyceride levels, a greater absolute difference
was noted.
n = 152 180
3822 (2.5%) 
CVD
n = 148 358
7260 (4.9%) 
and LLD use
n = 141 098
6998 (5.0%) 
non-
without CVD and LLD use




n = 133 540
Figure 1 Outline of exclusion route. This figure shows how
many and for which reasons participants were excluded. In total
18,640 individuals (12%) were excluded. CVD, cardiovascular
disease; LLD, lipid-lowering drugs.
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In the different age groups of men, median HDL-C
fluctuated between 46 and 54 mg/dL. In all age groups,
apart from 35 to 39 years, the 5th percentile was 35 mg/dL.
HDL-C did not significantly increase in older men. In
women, median HDL-C increased from 54 mg/dL at young
age (,20 years) to 66 mg/dL at the age of 50 years. Above
the age of 50 years, no changes in HDL-C levels werenoticed. The 5th percentile was 39 mg/dL in women aged
,45 years and 43 mg/dL in those aged $ 45 years.
Age, gender, and triglyceride levels
Of all lipids, the relation between triglycerides and age
showed the most pronounced differences between men and
women. In men, triglyceride levels strongly increased from
young age (median: 71 mg/dL; 95th percentile: 153 mg/dL)
until 40 to 44 years of age (median: 106 mg/dL; 95th
percentile: 289 mg/dL), thereafter, triglyceride levels drop-
ped rapidly with advancing age. Interestingly, this increase
was most prominent at the 75th, 90th, and 95th percentiles
and almost absent at the 5th and 10th percentiles. In sharp
contrast with the observations in men, triglyceride levels
in women were relatively stable and median levels fluctuate
between 68 and 77 mg/dL from 20 to 50 years of age. After
50 years of age, triglyceride levels increased moderately.
Reference values
Supplementary Tables 2 and 3 provide the (reference)
values of all blood lipids (including total cholesterol and
TC/HDL-C ratio) for men and women at five-year age in-
tervals. These reference values are also available at www.
my-cholesterol.care/. Supplementary Table 4 shows the ef-
fect of BMI on the age- and gender-specific 5th, 50th, and
95th percentiles.
Discussion
In this article, we describe the distribution of lipid and
lipoprotein levels in the general adult population of the
Netherlands. We anticipate that this large and unique cohort
will provide the scientific and clinical community valuable
new insights in the (near) future. Unique are the long and
frequent follow-up visits; every 1.5 years participants fill in
questionnaires, and every five years participants visit the
Lifelines research site for a physical examination and
biomaterial collection. Participants will be followed for at
least 30 years. More than 6,000,000 samples of biomate-
rials will be stored in the Lifelines biobank. The innovative
and unique three-generation design opens an exclusive
opportunity for the study of the environmental as well as
the genetic effects on lipid levels and CVD risk.
The presented lipid data from the Lifelines study
provide several important findings:
(1) The analysis shows prominent gender- and age-related
differences in all main plasma lipids and lipoproteins.
Our analysis reveals the need to correct for age and
gender when evaluating a lipid profile. Although these
observations are cross-sectional, and conclusions on the
true changes in lipids over time are hazardous, it is
interesting to note that our cross-sectional data are
comparable to the cross-sectional data from the Lipid
Research Clinics (LRC) Prevalence study (see in the
following).12,13
Table 1 Baseline characteristics of Lifelines cohort
Baseline characteristics Total (n 5 133,540)
Gender
P valueMen (n 5 54,065) Women (n 5 79,475)
Age (y) 43.8 (12.6) 44.1 (12.6) 43.5 (12.6) ,.001
SBP (mm Hg) 125 (15) 130 (14) 122 (15) ,.001
DBP (mm Hg) 74 (9.3) 76 (9.4) 72 (8.8) ,.001
BMI (kg/m2) 25.9 (4.3) 26.2 (3.6) 25.7 (4.7) ,.001
TC (mg/dL) 195 (170–220) 197 (174–224) 193 (166–220) ,.001
LDL-C (mg/dL) 124 (101–147) 131 (108–155) 116 (97–143) ,.001
HDL-C (mg/dL) 58 (46–66) 50 (43–58) 62 (50–73) ,.001
Triglycerides (mg/dL) 89 (62–120) 100 (72–144) 77 (58–105) ,.001
HbA1c (mmol/mol) 36 (34–39) 37 (34–39) 36 (34–39) ,.001
Smoking (%) 28,281 (21.2) 12,589 (23.3) 15,692 (19.7) ,.001
Physically active (%) 29,640 (23.6)* 11,815 (23.2) 17,825 (23.7) .020
Diabetes mellitus (%) 1458 (1.1) 571 (1.1) 887 (1.1) NS
DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NS, not significant; SBP,
systolic blood pressure; TC, total cholesterol.
Baseline characteristics of complete cohort and separate for men and women. Normally distributed variables are presented as mean and standard
deviation. Not normally distributed data are presented as median and interquartile range. Being physically active is defined as moderate physical activity
of 30 min/d. SI conversion factors: to convert cholesterol parameters to mmol/L, multiply values by 0.02586. To convert triglycerides to mmol/L, multiply
by 0.0113.
*A total of 7701 individuals did not answer this particular question.
Balder et al Age, gender and lipid levels 1059(2) High LDL-C is common in the northern provinces of
the Netherlands and the prevalence in young individ-
uals is higher than anticipated. Many (young) individ-
uals suffer from unknown hypercholesterolemia.
Based on these outcomes, strategies to improve these
modifiable risk factors need to be formulated at both
the individual as well as population level.
(3) The data presented in this study, and the accompanying
appendices, can be used as reference baseline values
for the standard lipoprotein parameters: total choles-
terol, LDL-C, HDL-C, and triglycerides. This will
facilitate the evaluation of (population) interventions
in the future and can be used as a comparator for other
prospective or retrospective lipid profile analyses in
different geographic regions. For use in clinical prac-
tice, an interactive Website is available at www.
my-cholesterol.care/.
Reference values in clinical practice
We value early identification of individuals with
increased LDL-C of utmost importance. Generating solid
scientific evidence that early (lifestyle and, in high-risk
individuals, pharmaceutical) intervention in primary care
is beneficial, proves to be extremely difficult. Attempts to
provide such evidence with one of the largest prospective
cohort studies, the Copenhagen study group (personal
communication with B.G. Nordestgaard) have failed
because of lack of power. However, it is in our opinion
a matter of common sense to reduce the burden of
unhealthy lifestyle behaviors early in life, especially in
individuals with LDL-C above the 95th percentile for age
and gender. It was recently shown that counseling for ahealthy lifestyle for five year led to lifelong (40 year) ben-
efits.14 Our data can be used to show individuals why they
must act to attenuate the potential increase of their high
LDL-C levels.
Using the cut-off levels of the 1st and 99th percentiles,
extreme lipid phenotypes can be identified, facilitating
early identification of hypercholesterolemia and hypocho-
lesterolemia in patients (and their families at increased
CVD risk). Further examination of these individuals would
allow for in-depth analysis of the underlying causes of
these severe dyslipidemias, generating opportunities to un-
ravel (novel) pathways that are related to hypocholesterole-
mia and hypercholesterolemia. Apart from LDL-C, our data
could also be of use in the identification of individuals with
extremely low HDL-C, which is a useful marker for poor
prognosis.15
Our study shows an impressive increase in LDL-C with
ageing. When using fixed LDL-C cut-off values, young
individuals with age- and gender-corrected very high
LDL-C are in peril of not being identified as having an
increased CVD risk. Why appropriate identification of
these young individuals is so important was shown in the
Atherosclerosis Risk in Communities study.16 Afro-
American individuals with a proprotein convertase subtil-
isin/kexin type 9 (PCSK9) loss of function mutation
presented with a 28% reduction in LDL-C, this translated
into an impressive 88% reduction of CVD risk. Caucasian
carriers of another PCSK9 loss of function mutation
presented with a reduction of only 15% in LDL-C levels,
but a striking 47% reduction in CVD risk. An explanation
for these remarkable observations is that individuals with
a loss of function mutations in PCSK9 benefit from
lifelong lower LDL-C levels.
Figure 2 Relations between age and levels of total cholesterol, LDL-C, and calculated LDL-C in men and women. The 5th, 10th, 25th,
50th, 75th, 90th and 95th age-specific percentile curves for total cholesterol, LDL-C, and calculated LDL-C (using Friedewald formula) in
men (left) and women (right). LDL-C, low-density lipoprotein cholesterol.
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To our knowledge, currently used lipid reference values
are largely based on the cross-sectional LRC Prevalence
study that was carried out in the 1970s.12,13 Figure 4 showsthe comparison of total cholesterol, LDL-C, and triglycer-
ides of these studies. In men, only very small differences
in total cholesterol between the studies were observed.
Women in Lifelines, however, presented with approxi-
mately 6.0 mg/dL lower total cholesterol levels between
Figure 3 Relations between age and levels of HDL-C and triglycerides in men and women. The 5th, 10th, 25th, 50th, 75th, 90th and 95th
age-specific percentile curves for HDL-C and triglycerides in men (left) and women (right). HDL-C, high-density lipoprotein cholesterol.
Balder et al Age, gender and lipid levels 1061the ages of 30 to 55 years. A similar pattern is also present
in distribution of LDL-C. Triglycerides seem to be lower in
the Lifelines study in all percentiles, however, the patterns
are comparable.
The similarity of the LDL-C distribution among both
studies is surprising in the context of the National Health
and Nutrition Examination Surveys (NHANES) showing
nation-wide improvements in lipid levels in the United
States over the past 60 years.17–19 This phenomenon may
also apply for the situation in the north of the Netherlands.
We can speculate that total cholesterol levels may have
been higher in our study population in the 1970s.
Alternatively, the Lifelines population may currently still
reflect the situation of the 1970s in the United States. We
have recently shown that the overall adherence to
guidelines is quite poor,20 and this could also apply to
improved lifestyle changes. In this regard, still 21% of
the population smokes tobacco. Another point that may
merit attention is that we have excluded individuals
reporting lipid-lowering medication. The use of lipid-
lowering drugs become more widely accepted after thePrevalence study, and lipid-lowering drug use certainly
have a huge effect on total cholesterol distribution curves.
Difference in the cholesterol analysis methods might also
explain the higher total cholesterol levels observed in
Lifelines. However, only in middle-aged females, total
cholesterol levels were lower. As this effect is gender
specific, it is unlikely to be related to differences in
methods of measurements only. This is not in-line with
an overall technical issue underlying our observations. It
should also be noted that not all population studies show
a decrease in cholesterol levels over time in all age groups.
For example, the Minnesota Heart Survey showed that
between 1980 and 2002, no changes in lipid levels were
present in individuals aged between 25 and 44 years.21 It
is likely that this also applies to the Lifelines population.
A direct comparison of mean calculated LDL-C levels
between NHANES22 and Lifelines population shows that
calculated LDL-C levels are similar across all age groups,
apart from 30 to 39 years, where LDL-C appears lower in
the Lifelines cohort (see Supplementary Table 5). LDL-C
means of the complete Lifelines cohort (including
1062 Journal of Clinical Lipidology, Vol 11, No 4, August 2017individuals reporting CVD and lipid-lowering drugs) are
more comparable to the NHANES study in comparison
to Lifelines individuals without CVD and lipid-lowering
drug use. The mean LDL-C levels from QuestionFigure 4 Comparing levels of total cholesterol, LDL-C, and triglyce
report, and the Lifelines study. The 5th, 25th, 50th, 75th, and 95th age-spec
are presented for the LRC Prevalence study (solid line),12 the AHA spe
men and women. LDL-C levels from Prevalence study and AHA specia
LRC, Lipid Research Clinics; AHA, American Heart Association.diagnostics23 are substantially lower across all age groups
(see Supplementary Table 5). This is probably due to
methodology: the latter population is a patient-based
sample.rides as measured in the LRC Prevalence study, the AHA special
ific percentile curves for total cholesterol, LDL-C, and triglycerides
cial report (dotted line),13 and Lifelines study (interrupted line), in
l report were similar. LDL-C, low-density lipoprotein cholesterol;
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In the Lifelines study, the median Friedewald LDL-C was
overall 7.0 mg/dL lower in men, and 6.0 mg/dL in women,
compared with direct LDL-C measurements. Many studies
have investigated the difference between direct measurement
and calculated LDL-C. It was shown in 27,331 healthy
women that direct measurement was also lower compared
with the Friedewald equation. However, both methods
showed similar association of LDL-C with CVD.24 In a large
American study, it was also shown that Friedewald-estimated
LDL-C levels were lower than the direct measurement, espe-
cially at low LDL-C levels (,70 mg/dL) and high triglycer-
ide levels.25 For an extensive and fair comparison, the
measurements should be compared with ultracentrifugation,
the golden standard. This process is however not suited for
large-scale routine use and therefore not available in our
cohort. In clinical practice, however, both the direct mea-
surement as the calculated LDL-C are often used. This anal-
ysis reemphasizes the need to answer the question whether
the Friedewald or direct measurement should be used in
treatment decisions.
Strengths and weaknesses
The large sample size of participants and the compre-
hensive data that are collected makes this a unique cohort
primed for translational research analysis. In Lifelines,
approximately one-third of the participants’ family members
participated, providing a unique opportunity to analyze
genetic traits. The Lifelines cohort is a large representative
sample of the general population of the north of the
Netherlands.26 Because of multiple recruitment strategies
including general practitioners’ patient files, family referral,
and self-registration, a representative study sample was
achieved. Lifelines is broadly representative on lifestyle, dis-
eases, and general health. The risk of selection bias is low.
However, middle-aged men and women are overrepresented.
Because we investigated the effect of age on gender on lipid
parameters, this could not have influenced our results.
A limitation is that the data set used is cross-sectional but
so far, references values were based on the likewise cross-
sectional (very similar) data of the LRC Prevalence study.
Naturally, prospective data will become available (earliest
autumn 2017). Generalizability of this study is limited
because participating was and is voluntary, so that the study
sample was self-selected. Another unfortunate limitation is
that the participants of Lifelines are almost exclusively of
Caucasian descent. Thus, our reference ranges will not be
applicable to other ethnicities: more than 98% of the Lifelines
cohort is of Caucasian Northern/West European descent.Conclusions
Our data show prominent differences in lipid profiles
between gender and age. This study provides tools, that is,gender- and age-specific reference values of contemporary
blood lipid levels (available at www.my-cholesterol.care/)
that may be used to identify young individuals with athero-
genic dyslipidemia, and therefore increased risk of CVD.
Acknowledgements
J.W.B. and I.M.N. had full access to all the data in the
study and take responsibility for the integrity of data and
the accuracy of the data analysis.Disclosure
The authors declare that they have no conflicts of
interest.References
1. GBD 2013 Mortality and Causes of Death Collaborators. Global,
regional, and national age-sex specific all-cause and cause-specific
mortality for 240 causes of death, 1990-2013: a systematic analysis
for the Global Burden of Disease Study 2013. Lancet. 2015;385:
117–171.
2. Nordestgaard BG, Chapman MJ, Humphries SE, et al, for the Euro-
pean Atherosclerosis Society Consensus Panel. Familial hypercholes-
terolaemia is underdiagnosed and undertreated in the general
population: guidance for clinicians to prevent coronary heart disease:
consensus statement of the European Atherosclerosis Society. Eur
Heart J. 2013;34(45):3478–3490a.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum
cholesterol and risk of premature death from coronary heart disease
continuous and graded? Findings in 356,222 primary screenees of
the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;
256:2823–2828.
4. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and
long-term cardiovascular and noncardiovascular mortality and life ex-
pectancy: findings for 5 large cohorts of young adult and middle-aged
men and women. JAMA. 1999;282:2012–2018.
5. Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of
low-density lipoprotein cholesterol, treatment strategies, and its
impact on cardiovascular disease morbidity and mortality. J Clin Lip-
idol. 2016;10:472–489.
6. Scholtens S, Smidt N, Swertz MA, et al. Cohort Profile: LifeLines, a
three-generation cohort study and biobank. Int J Epidemiol. 2015;
44(4):1172–1180.
7. Solhpour A, Parkhideh S, Sarrafzadegan N, et al. Levels of lipids and
apolipoproteins in three cultures. Atherosclerosis. 2009;207:200–207.
8. Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME. Trends in
lipids and lipoproteins in US adults, 1988-2010. JAMA. 2012;308:
1545–1554.
9. Eliasson M, Janlert U, Jansson JH, Stegmayr B. Time trends in popu-
lation cholesterol levels 1986-2004: influence of lipid-lowering drugs,
obesity, smoking and educational level. The northern Sweden MON-
ICA study. J Intern Med. 2006;260:551–559.
10. Kimberly MM, Leary ET, Cole TG, Waymack PP. Selection, valida-
tion, standardization, and performance of a designated comparison
method for HDL-cholesterol for use in the cholesterol reference
method laboratory network. Clin Chem. 1999;45:1803–1812.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concen-
tration of low-density lipoprotein cholesterol in plasma, without use of
the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
1064 Journal of Clinical Lipidology, Vol 11, No 4, August 201712. Plasma lipid distributions in selected North American populations: the
Lipid Research Clinics Program Prevalence Study. The Lipid Research
Clinics Program Epidemiology Committee. Circulation. 1979;60:
427–439.
13. Rifkind BM, Segal P. Lipid Research Clinics Program reference values
for hyperlipidemia and hypolipidemia. JAMA. 1983;250:1869–1872.
14. Holme I, Retterstol K, Norum KR, Hjermann I. Lifelong benefits on
myocardial infarction mortality: 40-year follow-up of the random-
ized Oslo diet and antismoking study. J Intern Med. 2016;280:
221–227.
15. Tada H, Kawashiri MA, Konno T, et al. Prevalence, clinical features,
and prognosis of patients with extremely low high-density lipoprotein
cholesterol. J Clin Lipidol. 2016;10:1311–1317.
16. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence varia-
tions in PCSK9, low LDL, and protection against coronary heart dis-
ease. N Engl J Med. 2006;354:1264–1272.
17. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total choles-
terol concentrations and awareness, treatment, and control of hyper-
cholesterolemia among US adults: findings from the National Health
and Nutrition Examination Survey, 1999 to 2000. Circulation. 2003;
107:2185–2189.
18. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total
cholesterol levels among US adults. The National Health and Nutrition
Examination Surveys. JAMA. 1993;269:3002–3008.
19. Rosinger A, Carroll MD, Lacher D, Ogden C. Trends in total choles-
terol, triglycerides, and low-density lipoprotein in US adults, 1999-
2014. JAMA Cardiol. 2017;2:339–341.20. Balder JW, Scholtens S, de Vries JK, et al. Adherence to guidelines to
prevent cardiovascular diseases: the LifeLines cohort study. Neth J
Med. 2015;73:316–323.
21. Arnett DK, Jacobs DR Jr., Luepker RV, Blackburn H,
Armstrong C, Claas SA. Twenty-year trends in serum cholesterol,
hypercholesterolemia, and cholesterol medication use: the
Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation.
2005;112:3884–3891.
22. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of
dyslipidemia and recommended lipid levels in US adults with
and without cardiovascular comorbidities: the National Health and
Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156:
112–119.
23. Kaufman HW, Blatt AJ, Huang X, Odeh MA, Superko HR. Blood
cholesterol trends 2001-2011 in the United States: analysis of 105
million patient records. PLoS One. 2013;8:e63416.
24. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL choles-
terol concentrations by Friedewald calculation and direct measure-
ment in relation to cardiovascular events in 27,331 women. Clin
Chem. 2009;55:888–894.
25. Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-
estimated versus directly measured low-density lipoprotein
cholesterol and treatment implications. J Am Coll Cardiol.
2013;62:732–739.
26. Klijs B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N.
Representativeness of the LifeLines Cohort Study. PLoS One. 2015;
10:e0137203.
Supplementary Figure 1 Absolute difference in calculated
Friedewald LDL-C and direct LDL-C measurement by triglycer-
ide strata. The absolute difference between Friedewald LDL-C
and direct measurement of LDL-C by triglyceride strata are pre-
sented as median (circles) and the 5th and 95th percentile (error
bars), separately for men (black) and women (white). Values
below zero indicate that the direct measurement is higher than
the Friedewald calculation and vice versa. To convert cholesterol
parameters to mmol/L, multiply values by 0.02586. To convert tri-
glycerides to mmol/L, multiply by 0.0113.
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18–19 842 1616 2458
20–24 1905 3995 5900
25–29 4638 6576 11,214
30–34 5302 7059 12,361
35–39 6485 9535 16,020
40–44 8822 13,129 21,951
45–49 10,049 14,789 24,838
50–54 5705 8289 13,994
55–59 3338 5166 8504
60–64 3227 4502 7729
65–69 2182 2794 4976
70–74 1013 1284 2297
75–79 383 520 903
$80 174 221 395
Total 54,065 79,475 133,540
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Supplementary Table 2 Age-specific percentile values for total cholesterol, LDL-C, HDL-C, TC/HDL-C ratio, and triglycerides in men
Percentile 1st 2.5th 5th 10th 25th 50th 75th 90th 95th 97.5th 99th
TC (mg/dL)
18–19 y 97 104 109 120 131 147 166 186 205 220 234
20–24 y 101 112 120 128 143 162 182 205 217 232 243
25–29 y 108 120 128 139 155 174 197 220 240 255 273
30–34 y 116 128 135 147 162 186 209 236 251 267 286
35–39 y 124 131 143 151 170 193 217 244 259 275 294
40–44 y 128 139 147 159 178 201 228 251 267 282 302
45–49 y 131 143 155 162 186 209 232 255 271 286 302
50–54 y 135 147 159 170 189 209 232 259 275 286 305
55–59 y 139 151 159 170 189 213 236 259 275 286 302
60–64 y 135 147 159 170 189 213 236 255 271 286 302
65–69 y 135 147 159 170 189 213 236 259 271 282 298
70–74 y 128 143 155 166 186 209 232 255 271 282 302
75–79 y 128 143 155 166 182 205 228 251 267 280 295
$80 y 139 145 151 159 178 197 220 244 259 267 296
LDL-C (mg/dL) direct measurement/calculated (Friedewald formula)
18–19 y 43/39 50/42 54/47 62/54 70/65 85/79 104/97 123/114 139/130 147/141 162/155
20–24 y 46/40 54/48 59/54 70/62 81/75 97/91 116/110 139/130 151/144 164/157 182/171
25–29 y 50/45 62/56 66/62 77/70 93/85 112/104 131/124 155/145 166/159 182/171 197/190
30–34 y 58/52 70/62 73/69 85/79 101/94 120/112 143/134 166/157 178/169 193/184 213/200
35–39 y 62/58 73/67 81/75 89/84 108/100 128/120 151/142 170/163 186/178 201/190 217/209
40–44 y 66/61 77/70 85/79 97/89 112/106 135/126 159/148 178/169 193/185 205/195 220/212
45–49 y 70/63 81/74 89/83 101/93 120/110 139/131 162/153 182/174 197/187 209/198 224/212
50–54 y 70/66 81/76 93/86 104/96 120/113 143/134 162/154 186/175 197/189 213/202 228/217
55–59 y 75/71 85/80 93/87 104/96 120/115 143/135 166/156 186/177 201/189 213/201 228/216
60–64 y 73/67 85/79 93/87 104/99 124/115 143/135 162/156 186/174 197/188 209/199 227/215
65–69 y 73/65 81/75 93/85 104/97 120/114 139/134 162/155 182/175 197/187 205/199 220/212
70–74 y 58/58 81/78 93/85 104/96 120/112 139/132 162/155 186/174 197/189 209/198 224/215
75–79 y 69/65 81/78 89/87 101/96 120/112 135/130 159/149 182/172 193/182 206/195 217/205
$80 y 73/67 80/75 89/83 97/88 108/104 131/125 147/143 178/169 183/180 196/197 213/209
HDL-C (mg/dL)
18–19 y 31 35 35 39 46 50 58 66 73 77 81
20–24 y 31 31 35 39 46 50 58 66 72 77 85
25–29 y 27 31 35 39 43 50 58 66 73 77 81
30–34 y 27 31 35 35 43 50 58 66 70 73 85
35–39 y 27 31 31 35 43 46 54 66 70 77 81
40–44 y 27 31 35 35 43 50 58 66 70 77 81
45–49 y 27 31 35 39 43 50 58 66 73 81 85
50–54 y 31 31 35 39 43 50 58 70 73 81 89
55–59 y 31 31 35 39 43 50 62 70 77 85 89
60–64 y 31 31 35 39 43 50 62 70 77 85 92
65–69 y 31 35 35 39 46 54 62 73 81 85 93
70–4 y 31 35 35 39 46 54 62 73 81 85 93
75–79 y 31 35 35 39 46 54 62 73 81 89 97
$80 y 27 32 35 39 43 50 62 73 81 89 97
TC/HDL-C ratio
18–19 y 1.75 1.88 1.95 2.15 2.46 2.83 3.37 3.93 4.42 4.82 5.33
20–24 y 1.81 1.95 2.10 2.25 2.63 3.09 3.79 4.55 5.14 5.64 6.46
25–29 y 1.90 2.10 2.25 2.46 2.86 3.47 4.25 5.11 5.80 6.40 7.21
30–34 y 2.00 2.19 2.38 2.63 3.11 3.78 4.60 5.50 6.11 6.78 7.75
35–39 y 2.12 2.30 2.53 2.79 3.31 4.00 4.91 5.91 6.56 7.30 8.25
40–44 y 2.11 2.36 2.56 2.85 3.40 4.15 5.09 6.00 6.70 7.40 8.33
45–49 y 2.11 2.35 2.56 2.85 3.44 4.18 5.08 6.00 6.60 7.14 7.89
50–54 y 2.14 2.39 2.60 2.92 3.44 4.17 5.00 5.89 6.50 7.13 8.00
55–59 y 2.14 2.35 2.59 2.85 3.38 4.13 5.00 5.83 6.43 7.00 7.83
60–64 y 2.18 2.41 2.60 2.88 3.40 4.07 4.85 5.67 6.20 6.77 7.44
(continued on next page)
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Percentile 1st 2.5th 5th 10th 25th 50th 75th 90th 95th 97.5th 99th
65–69 y 2.11 2.35 2.56 2.85 3.31 3.93 4.73 5.55 6.09 6.60 7.13
70–74 y 2.08 2.40 2.58 2.81 3.29 3.92 4.72 5.42 5.94 6.41 7.20
75–79 y 2.09 2.30 2.48 2.72 3.23 3.83 4.62 5.50 5.91 6.40 6.92
$80 y 2.14 2.24 2.30 2.62 3.25 3.85 4.61 5.50 5.77 6.57 7.64
Triglycerides (mg/dL)
18–19 y 27 32 35 41 52 71 94 124 153 187 221
20–24 y 31 35 40 47 58 78 105 144 177 220 291
25–29 y 32 37 42 50 63 85 123 172 222 280 376
30–34 y 35 39 43 52 67 94 136 193 241 304 398
35–39 y 35 42 47 54 72 100 148 216 267 335 468
40–44 y 37 42 48 57 75 106 156 230 289 367 517
45–49 y 39 44 50 58 77 108 158 226 282 350 436
50–54 y 38 44 50 59 78 107 152 220 278 359 488
55–59 y 39 44 50 59 77 105 147 205 254 322 439
60–64 y 41 45 51 59 76 102 140 190 235 286 365
65–69 y 40 44 50 58 74 99 136 183 227 276 334
70–74 y 42 46 52 58 73 96 129 172 222 266 344
75–79 y 38 45 50 57 72 92 125 167 207 261 301
$80 y 37 42 46 56 71 97 128 162 184 207 337
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC/HDL-C ratio, total cholesterol/HDL-C
ratio.
SI conversion factors: to convert cholesterol parameters to mmol/L, multiply values by 0.02586. To convert triglycerides to mmol/L, multiply by
0.0113.
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Supplementary Table 3 Age-specific percentile values for total cholesterol, LDL-C, HDL-C, TC/HDL-C ratio, and triglycerides in women
Percentile 1st 2.5th 5th 10th 25th 50th 75th 90th 95th 97.5th 99th
TC (mg/dL)
18–19 y 108 116 124 131 147 166 186 209 220 232 247
20–24 y 112 120 128 135 151 170 189 209 224 236 251
25–29 y 112 120 128 135 151 170 189 213 224 240 259
30–34 y 112 124 128 135 151 170 193 213 228 240 255
35–39 y 116 124 131 143 159 178 197 217 232 244 263
40–44 y 124 131 139 151 166 186 209 228 244 255 275
45–49 y 131 139 147 159 174 197 220 240 255 271 290
50–54 y 139 151 159 170 189 209 236 259 275 290 313
55–59 y 147 159 170 182 201 224 247 275 290 302 321
60–64 y 155 165 174 186 205 228 251 275 290 305 325
65–69 y 151 166 178 189 209 232 255 278 294 305 329
70–74 y 151 162 174 186 209 228 251 278 290 302 322
75–79 y 147 162 170 182 205 228 247 270 286 298 309
$80 y 153 166 170 182 209 228 247 271 282 294 314
LDL-C (mg/dL) direct measurement/calculated (Friedewald formula)
18–19 y 47/42 54/49 62/55 66/62 81/75 97/93 116/112 135/130 151/143 159/154 182/172
20–24 y 46/42 54/49 62/56 70/64 81/78 101/94 120/112 135/131 151/143 159/155 178/169
25–29 y 46/42 54/50 62/57 70/65 85/78 101/95 120/113 139/132 151/145 166/159 182/176
30–34 y 50/43 58/52 66/59 73/67 85/80 101/96 120/116 139/135 155/147 166/160 182/177
35–39 y 50/46 58/54 66/61 73/69 89/83 104/100 124/119 147/138 159/152 170/163 189/181
40–44 y 54/48 62/58 70/65 81/73 93/88 112/106 131/127 155/147 166/160 182/173 197/191
45–49 y 62/53 70/63 77/71 85/80 101/95 120/114 143/135 162/157 178/171 193/186 209/202
50–54 y 66/59 77/70 85/78 93/87 112/104 131/125 155/148 178/170 193/186 209/199 232/221
55–59 y 73/66 81/77 93/86 104/97 124/116 143/137 166/159 189/182 205/197 220/209 236/226
60–64 y 77/73 89/83 97/91 108/102 128/119 147/140 170/163 193/184 205/197 220/210 240/229
65–69 y 77/73 93/85 101/93 112/103 128/121 151/143 174/165 193/187 209/201 224/215 244/235
70–74 y 77/71 89/81 101/90 108/102 128/122 151/142 170/162 193/184 205/200 217/210 240/228
75–79 y 73/62 85/75 97/87 104/97 124/115 147/139 166/158 186/177 201/188 209/200 228/214
$80 y 81/71 87/77 97/90 104/99 128/119 147/138 166/160 189/180 205/191 220/211 236/228
HDL-C (mg/dL)
18–19 y 35 35 39 43 50 54 66 73 81 85 93
20–24 y 35 35 39 43 50 58 66 77 85 89 97
25–29 y 35 35 39 43 50 58 66 77 85 93 97
30–34 y 31 35 39 43 50 58 66 77 85 89 97
35–39 y 35 39 39 43 50 58 70 77 85 89 97
40–44 y 35 39 39 43 50 62 70 81 89 93 101
45–49 y 35 39 43 46 54 62 73 85 93 97 108
50–54 y 35 39 43 46 54 66 77 89 97 104 112
55–59 y 35 39 43 46 54 66 77 89 97 104 116
60–64 y 39 39 43 46 54 66 77 89 97 104 116
65–69 y 35 39 43 46 54 66 77 89 97 104 112
70–74 y 35 39 43 46 54 62 77 89 97 104 112
75–79 y 32 39 43 46 54 66 77 89 97 104 111
$80 y 35 39 43 46 54 66 77 89 93 97 108
TC/HDL-C ratio
18–19 y 1.76 1.90 2.00 2.17 2.50 2.93 3.50 4.17 4.67 5.17 5.73
20–24 y 1.74 1.86 2.00 2.13 2.47 2.93 3.50 4.09 4.50 4.92 5.62
25–29 y 1.74 1.86 2.00 2.14 2.45 2.88 3.47 4.17 4.69 5.20 5.83
30–34 y 1.73 1.89 2.00 2.17 2.47 2.93 3.54 4.23 4.78 5.33 6.10
35–39 y 1.75 1.89 2.00 2.17 2.47 2.93 3.54 4.25 4.82 5.33 6.09
40–44 y 1.75 1.89 2.05 2.19 2.53 3.00 3.68 4.42 5.00 5.55 6.33
45–49 y 1.76 1.94 2.06 2.25 2.60 3.10 3.77 4.58 5.18 5.73 6.50
50–54 y 1.83 2.00 2.13 2.30 2.67 3.21 3.93 4.79 5.39 6.00 6.67
55–59 y 1.87 2.03 2.21 2.41 2.80 3.40 4.14 5.00 5.50 6.06 6.70
60–64 y 1.92 2.11 2.26 2.48 2.88 3.44 4.21 5.00 5.58 6.08 6.82
(continued on next page)
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Percentile 1st 2.5th 5th 10th 25th 50th 75th 90th 95th 97.5th 99th
65–69 y 2.00 2.17 2.33 2.52 2.95 3.50 4.22 5.00 5.57 6.09 6.64
70–74 y 1.97 2.19 2.34 2.50 3.00 3.56 4.27 5.00 5.46 5.92 6.83
75–79 y 1.82 2.10 2.25 2.52 2.86 3.42 4.13 4.92 5.60 6.43 6.97
$80 y 2.06 2.22 2.36 2.50 2.85 3.33 4.12 4.92 5.75 6.11 6.55
Triglycerides (mg/dL)
18–19y 32 36 41 47 58 77 101 129 150 174 199
20–24 y 30 35 40 46 58 76 100 129 151 172 202
25–29 y 30 34 38 43 55 72 97 127 151 180 217
30–34 y 29 33 37 42 51 68 93 125 147 177 216
35–39 y 30 34 37 42 51 68 94 127 153 181 235
40–44 y 31 35 39 43 55 72 99 135 163 196 245
45–49 y 34 38 42 47 58 77 106 147 179 214 274
50–54 y 35 40 44 50 62 82 114 158 196 237 290
55–59 y 37 42 47 53 66 88 122 168 204 244 291
60–64 y 39 44 49 56 69 90 122 167 203 242 306
65–69 y 42 47 51 58 73 95 127 168 203 237 290
70–74 y 42 48 53 60 75 99 132 174 202 226 276
75–79 y 39 50 55 60 74 98 129 161 213 259 292
$80 y 40 47 51 62 73 93 123 172 210 235 253
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC/HDL-C ratio, total cholesterol/HDL-C ratio; TC, total
cholesterol.
SI conversion factors: to convert cholesterol parameters to mmol/L, multiply values by 0.02586. To convert triglycerides to mmol/L, multiply by
0.0113.
Supplementary Table 4 The fifth, median, and 95th percentile of LDL-C are presented for age and gender groups, but also for specific
BMI groups





,25 25–30 30–35 $35 ,25 25–30 30–35 $35
18–19 54–85–128 60–101–152 N/A* N/A 18–19 58–97–143 61–104–159 66–112–170 N/A
20–24 58–93–143 66–108–62 58–116–182 N/A 20–24 58–97–143 66–104–155 70–108–162 69–104–155
25–29 66–104–159 70–116–174 80–124–178 90–124–176 25–29 62–97–147 66–104–159 73–112–162 70–112–173
30–34 73–112–174 81–124–182 85–131–193 63–120–182 30–34 62–97–147 66–104–159 72–112–166 68–116–166
35–39 77–120–178 85–131–189 89–135–189 76–131–189 35–39 66–101–147 70–112–162 73–116–170 70–116–174
40–44 81–128–186 89–139–197 89–139–201 93–135–189 40–44 70–108–159 73–116–174 77–124–178 77–120–174
45–49 85–131–193 93–143–197 93–143–197 85–135–195 45–49 73–116–170 81–124–182 81–128–189 85–128–183
50–54 89–139–197 97–143–201 89–143–201 73–139–195 50–54 81–128–189 85–135–197 89–135–193 89–139–205
55–59 93–139–193 93–143–201 95–147–205 93–143–220 55–59 90–139–198 93–147–213 89–147–213 83–139–201
60–64 93–139–193 97–143–198 93–143–197 88–128–197 60–64 97–147–205 101–151–209 97–151–205 101–143–193
65–69 89–139–193 97–143–197 89–143–189 N/A 65–69 97–147–209 104–155–209 97–151–213 93–147–201
70–74 89–135–193 97–143–199 85–139–189 N/A 70–74 102–151–209 101–151–205 93–143–209 N/A
75–79 97–131–182 87–139–197 N/A N/A 75–79 97–151–205 93–143–197 104–51–197 N/A
$80 78–124–182 93–133–188 N/A N/A $80 95–143–205 97–153–207 N/A N/A
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; N/A, not applicable.
*N/A: ,60 individuals were present in these subgroups.
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Supplementary Table 5 Mean Friedewald LDL-C of NHANES 2003 to 2004 study in comparison to Question diagnostics population





population 2008–2011 (mg/dL)2 Lifelines I (mg/dL) Lifelines II (mg/dL)
20–29 104 95 99 99
30–39 120 107 110 108
40–49 124 111 120 119
50–59 123 111 133 130
60–69 126 104 140 130
70–79 119 97 138 123
LDL-C, low-density lipoprotein cholesterol; NHANES, National Health and Nutrition Examination Surveys.
Lifelines I: fasting Lifelines participants without cardiovascular disease and without statin use and triglyceride 400 mg/dL. Similar population as in
our study. Lifelines II: fasting Lifelines participants.
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